284 results about "Protein aggregation" patented technology

The provided is a biomineralization material for treating dentin hypersensitivity and promoting epitaxial growth of enamel and a use thereof. The biomineralization material includes following raw materials in parts by weight: 5-72 parts of a film-forming protein or a PEGylated film-forming protein, 4-67 parts of a water-soluble disulfide bond exchanger and 1-21 parts of a pH regulator. The present application proposes for the first time that the disulfide bond exchanger (e.g., cysteine (Cys)) without any toxicity may react with the film-forming protein or PEGylated film-forming protein. When a protein nano-coating with a mineralization regulating function is formed, no large number of macromolecular protein aggregates can be generated to block the dentin pores. The biomineralization material can permeate deeply into the exposed dentin pores, with the depth of 200-500 μm (the sealing depth of the protein coating reacting with TCEP is only about 40 μm).

The invention belongs to the technical field of cereal protein processing, and particularly relates to wheat gliadin with good color and luster and glutenin with high solubility as well as a preparation method and application of the wheat gliadin and the glutenin. According to the method, a cold water solubility control coupling one-step freezing purification technology is broken through, the concentration of ethanol and the temperature of the solution are controlled through cold water, the dissolving state and aggregation behavior of wheat gliadin are synchronously regulated and controlled, then freezing treatment and a one-step method are coupled to achieve controllable protein aggregation, precipitation and freezing, and the purposes of separation and purification are achieved. The technology is green, efficient, simple, convenient and energy-saving, the obtained alcohol-soluble protein is good in color and luster, and industrial production is easy to realize. Furthermore, a membrane separation coupling high-pressure microjet technology is broken through, and on the basis of a technology for obtaining a glutenin concentrated solution through membrane separation, the protein concentrated solution is directly treated by adopting an alkaline condition synchronous high-pressure microjet circulating modification method, so that the structural characteristics such as the scale and the surface hydrophobicity of the target protein and the aggregation behavior are further regulated and controlled; the glutenin is endowed with better solubility.

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

The invention provides a bispecific antibody and a purification method thereof. The purification method comprises the following steps: a) loading a sample containing a bispecific antibody to a affinity chromatographic column, and leaching and eluting; the biomacromolecules in the sample are adsorbed on the affinity chromatography column in the leaching stage, the biomacromolecules comprise antibodies, host cell proteins and protein aggregates, and the antibodies comprise bispecific antibodies and homodimers; separating the antibody from the affinity chromatography column in the elution stage, and collecting the eluate in the elution stage; b) loading the eluent to a hydrophobic membrane material, carrying out flow-through, and collecting a flow-through liquid containing the purified antibody; and the flow-through liquid used for flow-through contains 0.73 to 0.77 M of (NH4) 2SO4. The method can solve the problem that homodimers in bispecific antibodies are difficult to efficiently remove in the prior art, and is suitable for the field of antibody purification.

The present invention provides a polypeptide having disaggregase activity for use in medicine, wherein the polypeptide comprises the sequence SEQ ID NO: 1 or SEQ ID NO: 2, or a variant thereof that retains the disaggregase activity, more particularly for use in the prevention or treatment of a disease or disorder associated with protein aggregates in a subject. The invention also provides an expression vector encoding the polypeptide for the same use, and uses and methods for eliminating or preventing the formation of a protein aggregate in a protein-containing composition. The invention also provides the use of the polypeptide for imaging a protein aggregate and for the diagnosis and prognosis of a disease associated with protein aggregates.

The article of this design is a syringe equipped with a filter that can filter out solid matter in a medicine, and when administering the medicine, it can suppress the resistance to the injection of the medicine while capturing, for example, protein aggregates in the medicine.

The invention discloses a fusion antibacterial peptide BMAP18-BSN37 and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 1, and the amino acid sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 2. The fusion antibacterial peptide BMAP18-BSN37 gene is inserted into a pNZ8148 expression vector to construct a recombinant expression vector pUBB, so that protein aggregation or degradation in cells can be avoided, and the survival rate of strains and the stability of protein expression are improved. The method comprises the following steps: transferring a plasmid pUBB into a lactic acid bacteria NZ9000 strain through electrotransformation, and screening a recombinant lactic acid bacteria strain capable of expressing a fusion protein BMAP18-BSN37 to obtain a recombinant strain NZ-BB; the recombinant lactic acid bacteria NZ-BB strain shows a remarkable prevention effect in an animal infection model, and can effectively reduce bacterial colonization and relieve pathological injury; the Salmonella strain has the potential of being used as an animal feed additive, can reduce the use of antibiotics and chemicals, slow down the development of bacterial drug resistance, improve animal immunity and slow down intestinal inflammation caused by salmonella, and provides support for effectively preventing the health of livestock and poultry.

The invention discloses application of spermidine in preparation of an agent for resisting mitochondrial oxidative damage and copper death damage, and relates to the technical field of biology. The invention provides an application of spermidine in preparing an agent for resisting mitochondrial oxidative damage and copper death damage, and further provides an application of spermidine in inhibiting copper death induced by copper sulfate and relieving iron-sulfur cluster protein loss and ester acylation protein aggregation induced by copper accumulation. The spermidine can obviously relieve cell viability decline induced by copper sulfate, reverse ROS and MDA level increase and mitochondrial membrane potential decline induced by copper sulfate and relieve iron-sulfur cluster protein loss and ester acylation protein aggregation induced by copper accumulation, and has obvious effects of inhibiting mitochondrial oxidative damage and copper death. The invention provides a method for effectively relieving copper death of ovarian granular cells, and solves the problem that the existing antioxidant and cytoprotective agent for resisting mitochondrial oxidative damage generate side effects in the use process.

The invention discloses a process for preparing a liquid fertilizer from high-purity tryptophan fermentation waste liquid, and relates to the technical field of fertilizer preparation, and the process comprises the steps of pretreatment of tryptophan fermentation liquid, concentration of the fermentation waste liquid, component optimization and stabilization treatment. The first filtering operation can remove suspended particles and macromolecular impurities in the waste liquid, the second filtering operation can remove macromolecular substances such as protein aggregates and polysaccharides in the waste liquid, meanwhile, the light transmittance of the waste liquid is improved, and the recovery rate of tryptophan is improved. A low-frequency pulse electromagnetic field is applied into the fermentation tank, so that the permeability of microbial cell membranes can be enhanced, the uptake of microorganisms to substrates and the secretion of metabolites can be promoted, the fermentation efficiency can be improved, and the fermentation time of tryptophan fermentation liquor can be shortened.

The invention provides a preparation method and application of a compound protein preparation, and the preparation method comprises the following steps: dissolving a protein matrix in deionized water, adjusting the pH value to 8.0-8.5, firstly adding an antioxidant, and then adding an oxidant and a reducing agent to obtain a protein coupling solution; dissolving the whey protein isolate in deionized water, adding a thickening agent, stirring, and cooling to room temperature to obtain a proteoglycan composite water phase; and mixing the protein coupling solution and the proteoglycan composite water phase according to a preset proportion, adding the oil phase, carrying out homogenization treatment to form a high internal phase emulsion, carrying out freeze drying, and crushing into particles to obtain the powdery protein pre-preparation. The structural stability of protein molecules is remarkably improved, and protein aggregation and sedimentation are reduced, so that the physical and chemical stability of the protein preparation in the storage and use processes is effectively improved, and the problem of insufficient structural stability in the prior art is solved.

The invention belongs to the technical field of food processing, and particularly relates to a preparation method of high-solubility macadamia nut protein. The method comprises the following steps: uniformly mixing Australian hardness degreased powder with water, and adding composite alkali powder to enable the pH value to be 10.5-11 so as to obtain a mixed material liquid; then, carrying out high-energy medium grinding treatment on the obtained mixed material liquid, and adding citric acid to enable the pH to be 6.8-7.0, so as to obtain a protein solution; and finally, carrying out spray drying on the protein solution to obtain the macadamia nut protein. According to the method disclosed by the invention, large insoluble protein aggregates are dissociated into relatively small water-dispersed protein aggregates by combining acid-base activation with a high-energy medium grinding system, so that the macadamia nut protein is better dissolved, and the problems of poor dispersibility and functional properties of the macadamia nut protein are solved. In addition, the method is green and simple in treatment process, high in treatment efficiency, capable of meeting industrial production standards and capable of achieving continuous production.

Selection systems, such as selection systems for determining peptides that inhibit protein aggregation, peptides determined with the selection systems, and methods of using the selection systems and the peptides.

Disclosed is a novel class of fusion proteins to recruit the cell's innate chaperone machinery, specifically the Hsp70-mediated system, to specifically reduce TDP-43-mediated protein aggregation and associated protein conformational diseases.

The present invention relates to a low fat milk cream product wherein the product is an emulsion having: (a) between 1% and 5% by weight, preferably between 2% and 4% by weight of milk protein; (b) between 5% and 20% by weight, preferably between 10% and 18% by weight of fat; (c) between 0.002 wt% and 0.3 wt% of a mineral salt, such as between 0.03 wt% and 0.3 wt% of sodium chloride and / or between 0.002 wt% and 0.02 wt% of calcium chloride; (d) optionally between 0.1% and 3% by weight of a food additive, preferably a hydrophilic colloid, and (e) between 70% and 90% by weight of water; wherein the milk protein is contributed by (i) skimmed milk powder or milk protein concentrate or micellar casein.

The present invention relates to novel peptides and uses thereof, and more particularly to peptides having a length of 12 to 20 a.a. comprising an amino acid sequence designated as SEQ ID NO: 1 or 2, having the ability to inhibit the formation of abnormal protein aggregates, wherein 1 to 4 of the amino acids excluding glycine are L-type amino acids and the other amino acids are D-type amino acids.

The invention discloses a high-emulsification-activity gluten protein based on irradiation modification and a preparation method thereof in the field of wheat protein processing, and the method comprises the following steps: dispersing wheat gluten protein in deionized water, stirring to form a uniform suspension, adjusting the pH value, carrying out enzymolysis treatment on the suspension by using alkaline protease, and drying to obtain the high-emulsification-activity gluten protein. Centrifugally drying to obtain primary protein powder; dissolving the protein primary powder in an irradiation solvent to obtain a protein dispersion liquid, and irradiating the protein dispersion liquid by using cobalt-60 gamma rays as an irradiation source in an intermittent manner; and taking the irradiated protein dispersion liquid, and performing centrifugal drying to obtain the high-emulsification active gluten protein. The method comprises the following steps: firstly, carrying out limited hydrolysis on gluten protein by using protease to generate a smaller peptide fragment, so that the irradiation efficiency and the emulsion stability are improved; by adopting an intermittent irradiation treatment mode, protein aggregation caused by heat effect can be reduced, the emulsifying effect is improved, and the stability and adhesive force of an adhesive can be improved when the emulsion is applied to the adhesive.

Disclosed herein are multifunctional polypeptides comprising an optional signal peptide sequence, a cell penetrating peptide, an antigen binding domain (e.g., anti-synuclein, anti-tau, anti-huntingtin), and a programmable proteasome-targeting PEST motif, and methods for using these polypeptides in treatment of protein aggregation diseases, e.g., neurodegenerative diseases.

The invention discloses a construction method and application of a Lewy small body dementia animal model, and belongs to the technical field of animal model construction. The construction method comprises the following steps: obtaining a phosphatase and tensin homologous gene-induced kinase 1 gene knockout experimental animal A by using a gene editing technology, and carrying out hybrid breeding on the experimental animal A and an Alzheimer disease model experimental animal B simulating beta-amyloid protein (Abeta) pathology, and screening filial generations containing the Alzheimer disease related mutation and pink1 gene knockout at the same time. According to the constructed model, beta amyloid protein is deposited on the basis of pink1 gene knockout, beta-amyloid plaque (A beta) is used for inducing alpha-synuclein protein aggregation, Lewy bodies are widely generated in cortex and hippocampus, the occurrence and development process of DLB is simulated, and a reliable animal model is provided for disease mechanism research and treatment drug screening and development.

The present disclosure relates generally to compositions, systems, and methods for lysing blood samples comprising an infectious agent, for example a bacteria, or a fungus, while maintaining viability of the infectious agent for subsequent characterization, for example phenotyping or genotyping. A lysing composition may include one or more surfactants, such as one or more detergents. A lysing composition may include lysing agent including one or more salts. A lysing composition may include one or more enzymes to break down one or more lyses byproducts, such as nucleic acids and / or protein aggregates.

Provided herein is a method of decreasing a-syn levels and / or decreasing a-syn toxicity in a cell, the method comprising contacting the cell with a charged multivesicular body protein 2B: a-synuclein (CHMP2B:a-syn) inhibitor and a method of inhibiting neural degeneration, the method comprising administering to a subject in need thereof a charged multivesicular body protein 2B: a-synuclein (CHMP2B:a-syn) inhibitor.

The present disclosure provides anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that preferentially bind to soluble amyloid [beta] fibrils / oligomers and trigger ADPC in microglial cells; anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that reduce soluble amyloid [beta] fibril / oligomer levels and insoluble amyloid [beta] plaques in brain tissue; and the use of anti-A [beta] fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with A [beta] protein aggregation, in particular Alzheimer's Disease (AD).

Compounds comprising aminoindole carboxamide, compositions comprising same, and method of using such compounds and compositions to inhibit tubulin-associated unit (tau) protein aggregation or alpha-synuclein (a-syn) protein aggregation in a subject having, or at risk for, tau protein aggregation or a-syn protein aggregation, respectively.

The article of this design is a syringe equipped with a filter that can filter out solid matter in a drug, and can suppress the drug's injection resistance while capturing, for example, protein aggregates in the drug when administering the drug. In addition, by providing an inner stopper in the housing that moves when administering the drug, the drug filled in the cylinder does not come into contact with the filter during storage.

Compounds comprising an amide-linked coumarin scaffold, compositions comprising same, and method of using such compounds and compositions to inhibit tubulin-associated unit (tau) protein aggregation or alpha-synuclein ( α-syn) protein aggregation in a subject having, or at risk for, tau protein aggregation or α-syn protein aggregation, respectively.

The invention relates to methods and materials for use in treating neurodegenerative diseases associated with pathological protein aggregates and provides fusion proteins comprising: (i) a first portion comprising a sequence of a protein which aggregates pathologically in neurodegenerative disease, such as tau protein, and (ii) a second portion comprising a RING-type E3 ubiquitin ligase, a component of a RING-type E3 ubiquitin ligase complex, or a domain of either. These fusion proteins have utility in selectively or preferentially targeting pathogenic protein aggregates for degradation.

The present invention relates to a formulation of an Engrail (EN) protein, and more particularly to an aqueous formulation of an Engrail (EN) protein capable of inhibiting or minimizing aggregation of the EN protein. In some embodiments, the formulations of the present invention are capable of inhibiting or minimizing dimerization and / or oligomerization of an EN protein, which is a monomer.

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.

The article of this design is a syringe equipped with a filter that can filter out solid matter in a drug, and can suppress the drug's injection resistance while capturing, for example, protein aggregates in the drug when administering the drug. In addition, by providing an inner stopper in the housing that moves when administering the drug, the drug filled in the cylinder does not come into contact with the filter during storage.

The technical problem of the present disclosure is to provide: a composition for promoting the decomposition of protein aggregates; and a pharmaceutical composition for preventing or treating neurodegenerative diseases associated with the formation of protein aggregates. The technical problem is solved by a compound represented by general formula (I).

The invention discloses a phospholipid compound for inhibiting beta-amyloid protein aggregation, and the chemical structural formula of the phospholipid compound is as follows: # imgabs0 #, and n is an integer greater than 2. Dioleoyl phosphatidyl ethanolamine molecules are modified by utilizing maleimide alkyl carboxylic acid and glutathione, so that the interaction between a phospholipid compound and amyloid protein can be effectively regulated and controlled, and the aggregation of the amyloid protein is delayed and even inhibited; the preparation method is simple, the reaction energy consumption is low, and the obtained phospholipid compound has good biocompatibility and is suitable for popularization and application.